LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
نویسندگان
چکیده
We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed.
منابع مشابه
Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed promin...
متن کاملMicrocystic macular oedema in multiple sclerosis is associated with disease severity.
Macular oedema typically results from blood-retinal barrier disruption. It has recently been reported that patients with multiple sclerosis treated with FTY-720 (fingolimod) may exhibit macular oedema. Multiple sclerosis is not otherwise thought to be associated with macular oedema except in the context of comorbid clinical uveitis. Despite a lack of myelin, the retina is a site of inflammation...
متن کاملFingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.
BACKGROUND Fingolimod 0.5mg once daily is the first approved oral therapy for relapsing multiple sclerosis (MS). OBJECTIVE To report integrated long-term safety data from phase 2/3 fingolimod studies. METHODS Descriptive safety data are reported from the FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study, a 24-month, randomized, double-blind stud...
متن کامل[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and O...
متن کاملEvaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod
Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...
متن کامل